Contact us

If you have a medical information enquiry regarding any Roche products (pharmaceuticals), you can call us onor email your enquiry and contact details to 

Please note, we cannot respond to questions regarding personal medical conditions. If you have specific questions relating to your own health or to your own use of Roche medicines, devices or meters, please consult your physician/doctor.

Reporting suspected adverse reactions after authorisation of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product.  All adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre at  or callIf you need to report an adverse event with Tamiflu® (oseltamivir), please go to the Tamiflu® (oseltamivir) Adverse Event Reporting 

To report an adverse event related to a Roche Diabetes Care product please contact the relevant Accu-Chek Careline. 

To report an adverse event related to a CoaguChek meter please call(UK) /(Ireland) or email 

For all other Diagnostics products please call(UK) /or email 

Roche is required by law to document reports of adverse events, both for comprehensive safety monitoring of its products and also to fulfill reporting requirements to Regulatory Authorities. The information you have provided will be made anonymous, entered onto our Roche Drug Safety database by Roche Drug Safety staff, or Tata Consultancy Services staff based in India, who Roche have entered into contract with to provide drug safety monitoring services on its behalf, and processed in full compliance with UK Data Protection Legislation. It may be forwarded to the appropriate Regulatory Authorities in the UK and other countries by both Roche Drug Safety staff and Tata Consultancy Services staff who have been fully trained on Roche processes and procedures in an aggregated and anonymised format in accordance with the established guidelines. It may also be processed in the UK and other countries for the purposes of continually monitoring the safety of Roche’s medicines.

It may be forwarded to the appropriate Regulatory Authorities in the UK and other countries in accordance with the established guidelines. It may also be processed in the UK and other countries both within and outside of the EU for the purposes of continually monitoring the safety of Roche’s medicines.

If you have an press enquiry relating to our medicines please contact the hotline onor email

If your query is related to our diagnostic tests or instruments please contact us at

M-GB-00013232 Date of Preparation July 2023